Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
about
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastomaNuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastomaFocus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human gliomaThe natural history of EGFR and EGFRvIII in glioblastoma patientsImmunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersMolecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and TreatmentBiomarkers for glioma immunotherapy: the next generationDeregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsChallenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategiesModern brain tumor imagingCase comparison and literature review of glioblastoma: A tale of two tumorsTargeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastomaCIViC databaseA phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Current Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaMechanisms of action of therapeutic antibodies for cancerThe future role of personalized medicine in the treatment of glioblastoma multiformeEpidemiologic and molecular prognostic review of glioblastomaEGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell LineMultiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastomaNuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration.An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9.Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapyEGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Epidermal growth factor-induced enhancement of glioblastoma cell migration in 3D arises from an intrinsic increase in speed but an extrinsic matrix- and proteolysis-dependent increase in persistence.Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy.Incorporating molecular tools into early-stage clinical trialsiTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype.RNA interference and nonviral targeted gene therapy of experimental brain cancerClinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer.Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumorsA novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.Mig-6 controls EGFR trafficking and suppresses gliomagenesisZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain
P2860
Q24338526-80675501-AE4F-4663-A5FF-5AAEABA416E6Q24548280-F69E9DA9-258D-42F6-A638-6DF772B68EBCQ24615166-754055DB-070E-4695-B95E-6171985ED078Q24814477-E6357DD9-495C-4100-9755-D810ECCC175BQ26751473-2C70EB80-5403-40BE-AA9C-B57D9C611533Q26785952-25759542-BC84-4874-9D8B-F3D766E01CD2Q26825496-721AD52C-7171-4918-9556-C661A4309D60Q26829873-14EFAF93-0D86-448B-9E89-4716F2FE73E3Q26852366-A6A379B6-9133-495A-994E-8DC61A4D09AAQ27002344-B0134F07-41AC-43E5-82F7-0468C32B64E8Q27014996-05F771A0-4F32-4F91-AE39-89A5F73FB4D0Q27022941-2C84A05D-369F-4D78-988D-C78D6E4CC24AQ27612411-03072F6C-924A-401B-9A1E-59FD79494211Q27853118-BF6AEE34-4CFA-4F87-9FF7-196F00797251Q27853219-221F2FB4-7A36-476E-92E1-BD162C857582Q28087306-1F967F06-5FAB-44FB-A2FC-8FE1DD369CBBQ28385366-E17F9C33-B633-4BA2-A664-64461C68598BQ28391635-7F781AA0-D8B6-4DFE-ABE8-F60E76167458Q28395302-E99C1102-14C2-4401-B563-07F3273BF58AQ28551853-1F328B21-1304-45A0-A884-7A417D6B25CAQ30405446-CC9F589A-395B-4C91-8BFB-7E79A0FEDD23Q30416775-25F74B45-C564-4EB9-BB23-028AF058DB0AQ30431424-3113F3CC-5001-4FB3-8340-4A25A4D8D312Q30432036-7C92DF5F-FF87-41DB-B038-C590C7724006Q30437740-6030EB2F-DFF1-42A8-9D72-51CE6F401D6FQ30456087-0A77E16C-648E-49E5-BFBA-97A8237391C1Q30483791-D8F5D290-71B5-4FCF-BEA7-381D51FAF743Q30511916-36397E6F-2F4E-4C47-B658-C0F43CAED61AQ30872679-FF4407A1-DE69-4043-9CF0-3BA1EAAE72BBQ33316159-89464E10-B96F-4382-BB0B-BF5D353139A7Q33493026-03C6891F-953E-48F0-A0AB-2D46A33F4174Q33569727-230AA081-AA2C-4545-9AB4-2DE935771601Q33628302-1906A821-741A-420D-8E2D-DA23AC387E86Q33648830-F1EDD438-7BDE-4617-B6D8-8DF89CA22D5DQ33664297-13EA10BD-663F-4F58-920C-525B3823248EQ33753135-6445F6E1-378F-415C-B92C-50CE313573DDQ33777423-6CCA515D-4A6C-4236-8510-7EB190EAF078Q33809397-6B20FEEE-6B79-4FFC-ACBF-5CD22E745883Q33859568-276055F9-A162-4EAE-9070-65D3A2E01471Q33870872-71B89D7E-A7AB-49E6-BDB4-F83B0DACDC49
P2860
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Prognostic value of epidermal ...... with glioblastoma multiforme.
@ast
Prognostic value of epidermal ...... with glioblastoma multiforme.
@en
Prognostic value of epidermal ...... with glioblastoma multiforme.
@nl
type
label
Prognostic value of epidermal ...... with glioblastoma multiforme.
@ast
Prognostic value of epidermal ...... with glioblastoma multiforme.
@en
Prognostic value of epidermal ...... with glioblastoma multiforme.
@nl
prefLabel
Prognostic value of epidermal ...... with glioblastoma multiforme.
@ast
Prognostic value of epidermal ...... with glioblastoma multiforme.
@en
Prognostic value of epidermal ...... with glioblastoma multiforme.
@nl
P2093
P3181
P1433
P1476
Prognostic value of epidermal ...... s with glioblastoma multiforme
@en
P2093
Hideo Nakamura
Hideyuki Saya
Hirofumi Hirano
Jun-Ichi Kuratsu
Keishi Makino
Kenji Tada
Masato Kochi
Naoki Shinojima
Shoji Shiraishi
P304
P3181
P407
P577
2003-10-01T00:00:00Z